RedHill Biopharma reported $2.87M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Cara Therapeutics USD 19.85M 883K Mar/2026
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 10.28M 2.15M Jun/2026
Cronos Group USD 411.19M 55.83M Sep/2026
RedHill Biopharma USD 2.87M 1.75M Jun/2025